Navigation Links
Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
Date:11/12/2013

ncome (loss)

1115Accumulated deficit

(492,990)(436,804)Total stockholders' equity

28,73475,469Total liabilities and stockholders' equity

$
85,714$
39,154 Orexigen Therapeutics, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months Ended September 30, September 30, 2013201220132012Revenues:Collaborative agreement $

857$

857$

2,571$

2,571License revenue ----Total revenues 8578572,5712,571Operating expenses:Research and development 13,02725,80641,27645,428General and administrative 6,4115,65117,53714,905Total operating expenses 19,43831,45758,81360,333Loss from operations (18,581)(30,600)(56,242)(57,762)Other income (expense):Interest income 93657125Interest expense --(1)(2)Total other income (expense) 93656123Net loss $

(18,572)$

(30,564)$

(56,186)$

(57,639)Net loss per share - basic and diluted $

(0.19)$

(0.44)$

(0.59)$

(0.85)Shares used in computing net loss per share – basic and diluted 98,73770,15294,71767,982 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
2. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
3. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
4. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
11. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... WESTFORD, Mass. , July 30, 2014 ... in laser- and light-based aesthetic treatments for non-invasive and minimally ... promoted Executive Vice President, Chief Operating Officer and Chief Financial ... Company, effective August 1, 2014.  Baker, 53, will continue to ... from Michael Davin , who remains Chairman and Chief ...
(Date:7/30/2014)... and SAN DIEGO , July 30, 2014 ... ARNA ) announced today that an article based on post-hoc ... entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise ... published in the online issue of Obesity , the ... of these analyses was to identify whether there is an ...
(Date:7/30/2014)... /PRNewswire-iReach/ -- This is a professional and in-depth ... (CAS 9041-08-1) & calcium (CAS 37270-89-6) industry. The ... sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) including ... then explores global and China,s top manufacturers of ... listing their product specification, capacity, production value, cost, ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5
... July 29 IRIDEX Corporation (Nasdaq: IRIX ) today ... Trademark Office for U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use ... devices already in the IRIDEX product line, collectively identified and sold as ... , , ...
... For All® Inc., MMM Healthcare, Inc. (MMM) and ... access to medications, lab testing and medical imaging at substantial rate reductions ... , , ... that entitles users to savings that range as high as 50 to ...
Cached Medicine Technology:IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery 2IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery 3Free For All® Inc., MMM and PMC Assist Members with Pharmacy Discount 2Free For All® Inc., MMM and PMC Assist Members with Pharmacy Discount 3Free For All® Inc., MMM and PMC Assist Members with Pharmacy Discount 4
(Date:7/30/2014)... 2014 Good Neighbor Community Services ... upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , In this segment, ... Services’ vision to redefine the traditional approach to ... services. Through passion, innovation, determination, excellence, and collaboration, ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... IN (PRWEB) July 30, 2014 ... the opening of its new Carmel office on July ... staff will finally be moving to the state-of-the-art suite, ... cozy and innovative space will allow for one-on-one patient ... cosmetic surgery experience. , Dr. Hamilton’s new office-suite ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis and confirmed that many suffer psychological and physical symptoms long after ... a UCLA team led by Dr. Brennan Spiegel interviewed patients in great detail about the symptoms they experience weeks, months or even ...
(Date:7/30/2014)... 2014 As the controversy surrounding the ... surgeries continues to grow, Bernstein Liebhard LLP notes that ... for a ban on uterine morcellation. According to a ... with leiomyosarcoma following a hysterectomy that involved the use ... diagnosis, the aggressive cancer had progressed to Stage 4. ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
... Practice Guidelines (CPG) has recommended that waist circumference be ... that a national surveillance system be developed that incorporates ... ,This represents a landmark publication, as Canada is the ... guidelines to address the management and prevention of overweight ...
... body to address issues such as food quality and safety, ... ,"We have been concerned with integration of our food ... agencies, and hence we have recently enacted the Food Safety ... be administered by a single autonomous and scientific regulatory body," ...
... a heat wave with day temperatures in state capital ... shooting// up to 42 degrees Celsius. ,Roads ... Korba. In Raipur, people preferred to remain indoors while ... department has forecast a further rise in heat this ...
... agreed to lower the prices of Kaletra/Aluvia in low ... on a request from the World Health Organization’s Director-General ... the treatment of HIV-1 infected adults and children above ... antiretroviral agents. It is in a category of HIV ...
... obviously stressed. Who wouldn’t be with a daughter like Tracey! ... puffing her way through// a mountain of cigarettes three or ... Hunt, formerly Langton and Rachid) is a long-running character on ... by Anne Kirkbride since 1972. Deirdre has become synonymous with ...
... the Novartis case, the government of India is moving fast ... ,It has now been notified that all patent litigations filed ... amended Patent Act have been transferred to the Intellectual Property ... pharmaceutical companies have filed cases in High Courts and lower ...
Cached Medicine News:Health News:New Guidelines to Address Growing Obesity Epidemic 2Health News:New Guidelines to Address Growing Obesity Epidemic 3Health News:Abbott to Subsidize Price of HIV Drug 2Health News:Smoking on Television is Harmful to the Health of the Nation's Youth: BMA 2Health News:Smoking on Television is Harmful to the Health of the Nation's Youth: BMA 3Health News:Patents: Appellate Board Becomes Functional 2
The autoclavable, aluminum needle box is designed to store loaded needles and help protect personnel from exposure. Each shield consists of an aluminum box with faceplate to match the grid pattern th...
... The TheraSeed® Pd-103 implant is a combination ... remarkable visibility that makes TheraSeed® treatment an ... can be confident that every TheraSeed® implant ... services which is required by clinicians who ...
... Bard BrachyStar® Needle is designed to help ... and clinically effective brachytherapy procedure. All needles ... tips and polished surfaces for smooth entry ... configurations and sizes assures an ideal match ...
... is designed to help you achieve one ... brachytherapy procedure. All needles are engineered for ... surfaces for smooth entry and exit. A ... assures an ideal match with procedural needs ...
Medicine Products: